Quotes delayed, except where indicated otherwise. Currency in GBp.
Sphere Medical Holding plc (AIM:SPHR) is a medical devices company, providing monitoring and diagnostic devices for the critical care setting. Sphere’s flagship device Proxima is a patient-dedicated blood gas analysis solution for use in monitoring patients who are critically ill. It is typically used in the Intensive Care Unit and Operating Room and is highly differentiated, as blood is drawn from the patient over the sensor, but then returned to the patient.
The nurse can take a measurement without having to leave the patient’s bedside. The closed system has a number of benefits – in particular it conserves blood, reducing the possibility of hospital acquired anaemia and potentially the need for transfusions; the closed system also reduces the infection risk.
The first commercial version, Proxima 3, has been launched and achieved first sales. Proxima 4, which adds glucose monitoring to the existing panel, is applicable to around four times as many patients as Proxima 3; making it significantly more attractive to partners. Sphere remains on track for CE mark in 2016, with launch into Sphere’s direct markets (UK, Germany, Netherlands and Belgium) shortly afterwards.
Dr David Martyr (NE Chair)
CEO of Tecan AG, a Swiss listed laboratory instruments company valued at >CHF 1BN.
Dr Wolfgang Rencken (CEO)
Responsible for development & launch of many innovative medical devices. Previously CEO MAQUET Cardiopulmonary AG & COO Definiens AG.
Richard Wright (CFO)
20 yrs in financial roles. Previously 8yrs as FD Alliance Pharma plc.
John Gregory (Snr Ind Dir & NED)
NE Chair of Foresight VCT plc & NED or Chair of a number of private companies. Former Dir Singer & Friedlander Holdings.
Stephen H Mahle (former VP Medtronic Inc.), Meinhard Schmidt (held snr positions at Roche), Brenig Priest (20 yrs in finance & healthcare)
Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, today provides a commercialisation update for …
Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, announces its results for the year …
Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, is pleased to announce that it …
Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, is pleased to announce the appointment …
Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company,announces the launch today of Proxima 4 …
Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company,is today pleased to announce that all …
|Loss for the period||(5,465)||(5,347)|
|Cash & Equivalents||10,028||3,703
Deltex (AIM: DEMG)
manufactures & markets haemodynamic monitoring technologies.
LiDCO (AIM: LID)
Lombard Medical inc (NASDAQ: EVAR)
treatment of abdominal aortic aneurysms
Wolfgang Rencken – 0.32%
Stephen Mahle – 0.11%
Meinhard Schmidt – 0.13%
Dr David Martyr – 0.09%
Woodford – 28%
Arthurian Life Sciences – 17.64%
LSP Advisory – 7.69%
Johnson & Johnson – 5.74%
Octopus Investments – 4.41%
“The blood-gas and electrolyte analyser market was estimated at $3.2billion in 2014 and is growing about 4% per annum; driven by an increase in the number of critical care patients and measurement of a wider range of analytes.” (Panmure Gordon note, Feb 2016)
“The expected increase in population over the age of 65 would require a 52% rise in ICU beds to cope with demand. (Coke et al., Critical Care and Resuscitation, 2009).
“Sphere Medical Holdings, has managed to keep a steady hand on finances despite accelerating the commercialisation of its lead product, Proxima 3 and preparing for the launch of its nextgen solution.”
Panmure Gordon (Feb 2016 – House Broker)
“We believe the appointment of a distribution partner will substantially increase the share price, as in addition to validating the technology, it should provide access to a much wider range of customers, in new hospitals across different geographies enabling a faster growth rate.”
Trinity Delta (Feb 2016)
“Various generations of Proxima have been produced, with Proxima 3 being the first version to market (UK in 2014). However, it is the latest generation, Proxima 4, with added functionalities, that is expected to gain commercial traction.”